Global BCG Vaccine for Prevent Covid-19 Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global BCG Vaccine for Prevent Covid-19 Market Research Report 2024
As for March, 26 2020
Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals.The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.
1.BCG Clinical Trials for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers.Another team at the university of Exeter in the UK will conduct a similar study on older people.Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine."The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help."They said.
2.Introduction of BCG
The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries.Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others.But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies.The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented.A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.
3.BCG can "Train" Innate Immunity
The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory.The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections.In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.
According to Mr Accuracy reports’s new survey, global BCG Vaccine for Prevent Covid-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG Vaccine for Prevent Covid-19 market research.
Key manufacturers engaged in the BCG Vaccine for Prevent Covid-19 industry include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of BCG Vaccine for Prevent Covid-19 were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole BCG Vaccine for Prevent Covid-19 market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Prevent Covid-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
InterVax
Serum Institute of India
GreenSignal
Statens Serum Institute
Shanyao Group
Shanghai Institute of Biological Products
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The BCG Vaccine for Prevent Covid-19 report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals.The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.
1.BCG Clinical Trials for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers.Another team at the university of Exeter in the UK will conduct a similar study on older people.Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine."The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help."They said.
2.Introduction of BCG
The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries.Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others.But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies.The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented.A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.
3.BCG can "Train" Innate Immunity
The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory.The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections.In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.
According to Mr Accuracy reports’s new survey, global BCG Vaccine for Prevent Covid-19 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole BCG Vaccine for Prevent Covid-19 market research.
Key manufacturers engaged in the BCG Vaccine for Prevent Covid-19 industry include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of BCG Vaccine for Prevent Covid-19 were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole BCG Vaccine for Prevent Covid-19 market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global BCG Vaccine for Prevent Covid-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Sanofi Pasteur
Japan BCG Lab
China National Biotec
InterVax
Serum Institute of India
GreenSignal
Statens Serum Institute
Shanyao Group
Shanghai Institute of Biological Products
Segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The BCG Vaccine for Prevent Covid-19 report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices